FDA staff flags concerns about Capricor's Duchenne heart disease therapy - Reuters
FDA staff flags concerns about Capricor's Duchenne heart disease therapy Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQVnBOS1RYdGpTaVNfVHVYVExxdTl4OGtNX3ZUYTNTYmZjRmdTeEpsdlM5cUhkNW94OE1najhrVEhMVFUyenBJb0ptMElPNG9GcTc3NDJueGEyOG5MS3ZWeFlzdWhvbFRIdlNNWkRWV1VxTGlzX2Y3VGhJcmFMVjNQT0VETFRWekpiSkN0NTY3UkNEcXp1dmd6ZEZYSGhmdE9oXzdOYmh4NEZuYklGUjBBRTM4SVRvOVNxTzNQZUVYLXllRkQtUW1WSm1kcGtJaHF3cHBF?oc=5" target="_blank">FDA staff flags concerns about Capricor's Duchenne heart disease therapy</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues - Reuters
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues Reuters
October 2, 2026 at 09:52 PMUS FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PMUniQure plunges as Huntington's trial data disappoints investors - reuters.com
UniQure plunges as Huntington's trial data disappoints investors reuters.com
September 29, 2026 at 10:11 PMFDA seeks scientists and consumer representatives for advisory panels - reuters.com
FDA seeks scientists and consumer representatives for advisory panels reuters.com
September 30, 2026 at 08:30 PMNovo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - reuters.com
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro reuters.com
September 29, 2026 at 09:49 PMExperimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
September 30, 2026 at 05:34 PM